IL18 and neoplasm: IL-15 activates mTORC1 through IL-15-PI3K-AKT pathway, reversing glycolysis inhibition.112,121 Additionally, IL-12, IL-18, type I IFNs and Nrf2 activators have also been found to enhance the anti-tumor activity of NK cells in the TME.115,122,123